News

In the latest market close, CVS Health (CVS) reached $65.45, with a +0.43% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 2.51%. Meanwhile, the Dow experienced a rise of 2.66%, and the technology-dominated Nasdaq saw an increase of 2.71%.

Heading into today, shares of the drugstore chain and pharmacy benefits manager had lost 3.55% over the past month, outpacing the Medical sector's loss of 11.09% and the S&P 500's loss of 8.86% in that time.

Investors will be eagerly watching for the performance of CVS Health in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 1, 2025. The company is predicted to post an EPS of $1.65, indicating a 25.95% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $92.95 billion, up 5.1% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.89 per share and a revenue of $388.11 billion, indicating changes of +8.67% and +4.1%, respectively, from the former year.

Investors might also notice recent changes to analyst estimates for CVS Health. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.12% increase. Right now, CVS Health possesses a Zacks Rank of #3 (Hold).

Digging into valuation, CVS Health currently has a Forward P/E ratio of 11.06. This indicates a discount in contrast to its industry's Forward P/E of 14.87.

It's also important to note that CVS currently trades at a PEG ratio of 0.98. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical Services was holding an average PEG ratio of 1.18 at yesterday's closing price.

The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 42% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CVS Health Corporation (CVS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.